ArteraAI
PrivateLast Round
VC Round
Feb 1, 2024
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ArteraAI operates in Healthcare & Life Sciences and is based in Los Altos, California. Its latest recorded funding round was a VC Round in February 2024.
ArteraAI is a precision medicine company that develops AI-enabled predictive and prognostic cancer tests to personalize therapy for cancer patients.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Medical AI, Biotechnology, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ArteraAI Comparables
Compare ArteraAI with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Valar Labs | 79% | |
| Avenda Health | 74% | |
| Nanostics Inc. | 73% |
For institutional investors. Book with your work email.
ArteraAI Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Feb 1, 2024 | ||||
| VC Round | Mar 21, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ArteraAI Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Breyer Capital | VC Round |
| TIME Ventures | VC Round |
| Koch-ventures.com | VC Round |
| EDBI | VC Round |
| A&E Investments | VC Round |
| Walden Catalyst | VC Round |
| Koch Disruptive Technologies | VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 60% MoM.
- Dec 9, 2025
Launched ArteraAI Prostate Test (Post-RP) for biochemical recurrence.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 25, 2026
Artera Inc. is featured in five abstracts presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting in California on Sep 25th '26, highlighting its MMAI platform's prognostic and predictive power in prostate cancer.
- has_revenueSep 2, 2026
In 2025, Artera Inc. reaches $34.3M in revenue.
For institutional investors. Book with your work email.
ArteraAI Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ArteraAI's valuation, stock price, and market status.
Is ArteraAI a public or private company?
ArteraAI is a private company.
What is the current stock price of ArteraAI?
ArteraAI is a private company, so its shares have no public market price. Caplight tracks ArteraAI's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ArteraAI worth (valuation)?
Valuation information for ArteraAI is not publicly available.
Can I buy ArteraAI stock?
ArteraAI shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ArteraAI's last funding round?
ArteraAI's most recent funding round was VC Round on February 1, 2024.
Who are the main investors in ArteraAI?
Key investors in ArteraAI include TIME Ventures, EDBI, Koch Disruptive Technologies, Aramco Ventures, Factory.
Will ArteraAI IPO soon?
No public IPO plans have been announced for ArteraAI.
How can I track ArteraAI secondary market activity?
Caplight tracks bids, offers, and trades in ArteraAI's shares on secondary markets.